Informasi Perusahaan

Mengenal Alfa Invest

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal Alfa Invest

Alfa Invest Ltd operates as an online trading broker providing retail clients with access to global financial markets. The company offers a range of trading instruments, including foreign exchange pairs, global stock indices, commodities like oil and gold, and individual stocks, all through the mechanism of CFDs. It utilizes the popular MetaTrader 5 (MT5) platform for trading. The company's stated mission is to provide a transparent, reliable, and user-friendly trading environment for both novice and experienced traders. It is registered as an International Business Company (IBC) in St. Vincent and the Grenadines.

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Keuangan Layanan Lainnya

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Perusahaan belum memperbarui informasinya.

LAYANAN INI TIDAK TERSEDIA DI WILAYAH ANDA

Alfa Invest

Turki

Didirikan

2022 (4 Tahun)

Ditemukan

Terakhir online: Tidak ada aktivitas terbaru

Klaim perusahaan Kunjungi Situs Web

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

SKOR KESELURUHAN

Lisensi

--/40

Ulasan

--/60

0 ulasan

Disediakan oleh TrustFinance

TrustScore tidak tersediaSkor belum cukup untuk menampilkan tren.

Jadilah yang pertama memberi rating dan ulasan untuk perusahaan ini.

TrustFinance bukan penasihat keuangan berlisensi dan tidak berafiliasi dengan lembaga keuangan mana pun di wilayah Anda. Kami menyarankan Anda melakukan riset sendiri sebelum membuat keputusan investasi.

FTD LIMITED

(505 ulasan)

British Virgin Islands

2017

(9 tahun)

Informasi Keamanan :

BVI FSC

Informasi Keamanan

Peringatan

Perusahaan ini saat ini Belum Terbukti.

Harap berhati-hati terhadap potensi risiko!

Lisensi

Lisensi Kelas A

Dikeluarkan oleh regulator terkenal secara global, lisensi ini memastikan perlindungan pedagang tertinggi melalui kepatuhan yang ketat, pemisahan dana, asuransi, dan audit rutin. Penyelesaian sengketa dan kepatuhan terhadap standar AML/CTF semakin meningkatkan keamanan.

Lisensi Kelas B

Diberikan oleh regulator regional yang dihormati, lisensi ini menawarkan langkah-langkah keamanan yang kuat seperti pemisahan dana, pelaporan keuangan, dan skema kompensasi. Meskipun sedikit kurang ketat daripada Tingkat 1, lisensi ini memberikan perlindungan regional yang dapat diandalkan.

Lisensi Kelas C

Dikeluarkan oleh regulator di pasar negara berkembang, lisensi ini menawarkan perlindungan dasar seperti persyaratan modal minimum dan kebijakan AML. Pengawasan kurang ketat, sehingga pedagang harus berhati-hati dan memverifikasi langkah-langkah keamanan.

Lisensi Kelas D

Dari yurisdiksi dengan pengawasan minimal, lisensi ini seringkali tidak memiliki perlindungan utama seperti pemisahan dana dan asuransi. Meskipun menarik untuk fleksibilitas operasional, lisensi ini menimbulkan risiko yang lebih tinggi bagi pedagang.

Informasi Perusahaan

Mengenal Alfa Invest

Tampilkan Lebih Banyak

Informasi Perusahaan

Mengenal Alfa Invest

Tampilkan Lebih Banyak

Industri

Valuta Asing Pialang RitelUTAMA
Keuangan Layanan Lainnya

Perangkat Lunak

Tidak ada data yang tersedia

Sepertinya bagian ini kosong. Segera kembali untuk pembaruan!

Kontak

Sosial

Perusahaan belum memperbarui informasinya.

Pengguna yang melihat Alfa Invest juga melihat…

IUX

XM

FXGT

Deriv

Exness

IUX

XM

FXGT

Deriv

Exness

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: Jun 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Disediakan oleh Analisis AI TrustFinance

Ulasan

Alfa Invest Ulasan

Ulasan

Total 0

Analisis Tinjauan AI

Mari biarkan TrustFinance AI merangkum semua ulasan untuk Anda.

Disediakan oleh Analisis AI TrustFinance

Urutkan berdasarkan

Filter

Berita

TrustFinance Badan Intelijen

Tanggal penelitian: Jun 28, 2026

S&P Global Ratings upgraded Alfa S.A.B. de C.V.'s credit rating from 'BBB-' to 'BBB' following the completion of its spin-off from Alpek S.A.B. de C.V., improving its business structure and leverage. The stable outlook reflects expectations of continued support from its subsidiary Sigma, which is now responsible for Alfa's financial health. Alfa's debt decreased significantly post-spin-off, and the ratings agency anticipates stable cash flow and prudent financial policies from Sigma for the next two years. Future ratings could be affected by Sigma's performance and Alfa's liquidity management.

The article explains the concept of alpha in investment, which measures the excess return of a portfolio compared to its expected return based on the capital asset pricing model (CAPM). It discusses how alpha helps investors evaluate the performance of portfolio managers by comparing realized returns with required returns adjusted for risk. A positive alpha indicates better-than-expected performance, while a negative alpha suggests underperformance. The article also emphasizes the importance of comparing funds within the same asset class and using appropriate benchmarks for accurate assessment.

Bicara Therapeutics Inc. announced three-year follow-up results from its Phase 1/1b study of ficerafusp alfa combined with pembrolizumab for treating HPV-negative head and neck squamous cell carcinoma (HNSCC). The study, presented at the ASCO26 medical conference, showed sustained deep responses in about 90 patients, marking a significant development in immuno-oncology. The company also launched the FORTIFI clinical trial targeting this patient group, reflecting its commitment to addressing unmet medical needs.

Disediakan oleh Analisis AI TrustFinance